Figure 7
LDE225 + nilotinib administration significantly reduces leukaemia stem and progenitor cells in the spleen of BCR-ABL expressing mice.
(A) Schema for experiments using the EGFP+ /SCLtTA/TRE-BCR-ABL mouse model to assess drug efficacy in vivo. (B) Representative FACS plot for LSK and LTHSC cells. (C) Survival of mice after discontinuation of treatment. (D) Results of transplantation of BM and spleen cells obtained after treatment (cells pooled from 8 mice, 5 × 106 cells injected per recipient mouse, 8 mice per condition for both BM and spleen cells) into wild-type (wt) FVB/N mice. WCC and engraftment was monitored by drawing PB every 4 weeks. The fraction of recipient mice showing evidence of leukemia within 16 weeks after secondary transplantation was shown for (i) BM cells and (ii) spleen cells. Results represent the mean ± SEM for multiple samples. Significance values; *p < 0.05; **p < 0.01; n = 8.
